Skip to main content
PGNY
NASDAQ Industrial Applications And Services

Progyny 10-Q: Q3 Net Income $26.3M, $230.9M Buyback, CEO/Chairman 10b5-1 Plans

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$30.6
Mkt Cap
$2.309B
52W Low
$16.1
52W High
$33.065
52W Position info
90% above low
Off High info
7.5% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

PGNY sits 90% above its 52-week low of $16.1.

Summary

Progyny's Q3 10-Q confirms net income of $26.3M ($0.32 diluted) on $341.3M revenue, with $230.9M of buybacks in nine months and new 10b5-1 plans covering up to 1.97M CEO shares and 1.3M Chairman shares.


Key Events · Earnings and Guidance · PGNY

  • Q3 Profit Nearly Doubles

    Net income of $26.3M versus $13.9M a year ago, on revenue of $341.3M (+9%); diluted EPS $0.32 versus $0.15.

  • Margins Expand on Lower Stock Comp

    Gross margin rose to 24.5% from 23.2% and G&A fell 9% to $30.5M, helped by stock-based compensation dropping to $21.1M from $32.2M.

  • Aggressive Buyback Shrinks Share Count

    9,681,135 shares repurchased in nine months at an average $23.83 for $230.9M; $85.8M remains under the May 2026 program, and Q3 alone bought 2,980,798 shares at $27.73.

  • Large Insider Selling Programs Set

    CEO Pete Anevski adopted a 10b5-1 plan for up to 1,970,286 shares and Executive Chairman David Schlanger for up to 1,300,000 shares, both running to October 31, 2027.


Analysis · PGNY · Industrial Applications And Services

The headline numbers were already out on November 4, but the 10-Q is where the quality of the quarter shows: net income nearly doubled to $26.3M from $13.9M, gross margin rose to 24.5% from 23.2%, and nine-month operating cash flow held at $153.0M even after $32.6M of cash taxes. The company is also shrinking its share count fast — 9.68M shares repurchased for $230.9M in nine months at an average $23.83, with $85.8M still authorized — which is what makes the per-share earnings growth outpace the 9% revenue growth. Against that, the filing formalizes large pre-set selling programs: the CEO can sell up to 1,970,286 shares and the Executive Chairman up to 1,300,000 through October 2027, so insider supply will be a persistent overhang even as the company buys back stock.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PGNY was trading at $30.60 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $16.10 to $33.07. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PGNY - Latest Insights

PGNY
Nov 05, 2026, 4:27 PM EST
Filing Type: 144
Importance Score:
7
Price at Filing: $34.37
Real-time Price: $36.86 info
Change: +$2.49 (+7%) info
Market Cap: $2.611B info
PGNY
Nov 04, 2026, 4:12 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $30.10
Real-time Price: $36.86 info
Change: +$6.76 (+22%) info
Market Cap: $2.611B info
PGNY
Nov 04, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $30.04
Real-time Price: $36.86 info
Change: +$6.82 (+23%) info
Market Cap: $2.611B info
PGNY
Aug 07, 2026, 9:00 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $26.24
Real-time Price: $36.86 info
Change: +$10.62 (+40%) info
Market Cap: $2.611B info
PGNY
Aug 06, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.83
Real-time Price: $36.86 info
Change: +$10.03 (+37%) info
Market Cap: $2.611B info